Demand for efficient tech transfer, as well as compliant on-time delivery, is rising.

Tech Transfer and Regulatory Compliance

A look into the latest developments in biopharmaceutical manufacturing and facilities.

Update on Facilities and Manufacturing Trends

CDMOs are actively exploring and leveraging both new and existing technologies to streamline the cell-line development process at every step.

 It’s Time for CDMOs to Embrace the CRISPR Advantage

Topic

Feliza Mirasol is the science editor for 

Articles

MilliporeSigma has expanded its biosafety testing laboratories in Shanghai, China, with the completion of new lab space at its new €29 million (US$43 million) Biologics Testing Center.

MilliporeSigma Expands Biologics Testing Center in China

Chris Spivey is the editorial director of 

PharmTech Europe discusses technology that enables the “democratization” of mRNA manufacturing with Scott Ripley, general manager, Nucleic Acid Therapeutics and Precision Nanosystems, Cytiva, at the 11th International mRNA Health Conference in Berlin, Germany.

Democratizing GMP Manufacturing for the New Therapeutic Pipeline

A look into the latest developments in biopharmaceutical manufacturing and facilities.


Jinhyeok Jeong is senior director of Drug Product Inspection and Packaging at Samsung Biologics.

John Thomas is senior director of Drug Product MSAT at Samsung Biologics.

It’s Time for CDMOs to Embrace the CRISPR Advantage

As part of a $30 million investment, Aragen is setting up a new biologics manufacturing facility in Bangalore, India.

Aragen to Establish $30 Million Biomanufacturing Facility in India

Matthew Hewitt is vice-president, technical officer, Cell & Gene Therapy & Biologics at Charles River Laboratories.

Larry Bellot, PhD, is scientific advisor, Cell and Gene Therapy, at Charles River Laboratories.

Chad Andersen is associate director, Manufacturing Sciences & Technology, at Charles River Laboratories.

A look at using best practice tech transfer methods for CGTs to increase process and analytics robustness while being scalable.

Best Practice Tech Transfer Methods for CGTs

Under an expanded agreement, Cellares will provide proof-of-concept manufacturing for a second CAR-T cell therapy from Bristol Myers Squibb.

Cellares Expands Agreement with Bristol Myers Squibb for Second CAR-T Program 

The newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions.

Advent International, Warburg Pincus Complete $4.25 Billion Acquisition of Baxter’s BioPharma Solutions Business

Editor of Pharmaceutical Technology Europe

Samsung Biologics and Bristol Myers Squibb have further expanded their strategic manufacturing agreement to include the large-scale manufacture of an antibody cancer drug substance. 

Outsourcing

Tech Transfer and Regulatory Compliance

Update on Facilities and Manufacturing Trends

It’s Time for CDMOs to Embrace the CRISPR Advantage